Regeneron’s (REGN) odronextamab was granted FDA orphan designation as a treatment of splenic marginal zone lymphoma, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Resilient Outlook: Regeneron’s Strong Financial Projections Amid Foundation Closure Challenges
- Regeneron price target lowered to $940 from $950 at Guggenheim
- Regeneron price target lowered to $1,081 from $1,150 at Morgan Stanley
- Regeneron Faces Financial Challenges Amid Co-Pay Assistance Funding Shortfall, Prompting Sell Rating
- Regeneron price target lowered to $925 from $950 at Oppenheimer